Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Sara Hurvitz, SABCS 2021: Efficacy and Safety Findings of the coopERA Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 14th 2021

Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the coopERA study.

Questions
1. What is giredestrant, and what is the rationale for its use in HR+, HER2− early breast cancer? 00:14-01:14
2. Could you tell us a little about the coopERA clinical study and its findings? 01:15-04:30

Speaker Disclosure: Sara Hurvitz has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the San Antonio Breast Cancer Symposium 2021

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup